![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
Order Only Private message to Alice
Oct. 8th, 2014 09:55 pmTwo weeks ago, Miss Granger informed me that while she and Mr Malfoy were in Greater Hangleton, they found a number of Sleepers, from the initial wave, who had been overlooked by the cleanup crews. Yesterday she and I returned for inspection and for her to show me the site.
We counted one hundred thirteen Sleepers, to my eye distributed roughly as:
All ages are approximate and estimated to my best capacity.
With your permission, I propose to select five of the most healthy-appearing young adults of the 21-30 cohort and transport them to Moddey for a more thorough investigation. I believe the risk of that operation to be low; Miss Granger and Mr Malfoy are correct in that the town appears to be deserted and unwatched.
Once we have secured our patients, I will prepare a thorough assessment of the state of our research and we can decide from there how to proceed. The summary: the versions of the antidote we are iterating through at the moment are not yet ready for human trial, but we have solved the toxicity problems and I believe we are close to a version that will either function wholly or not at all, thus reducing the risk of our first human subject sustaining damage or resulting in a burden of future care. The level of my confidence in that statement vacillates from day to day, of course.
We counted one hundred thirteen Sleepers, to my eye distributed roughly as:
| Age | №. |
| 0-10 | 11 |
| 11-20 | 15 |
| 21-30 | 27 |
| 31-40 | 21 |
| 41-50 | 13 |
| 51-60 | 16 |
| 61-70 | 4 |
| 70+ | 6 |
All ages are approximate and estimated to my best capacity.
With your permission, I propose to select five of the most healthy-appearing young adults of the 21-30 cohort and transport them to Moddey for a more thorough investigation. I believe the risk of that operation to be low; Miss Granger and Mr Malfoy are correct in that the town appears to be deserted and unwatched.
Once we have secured our patients, I will prepare a thorough assessment of the state of our research and we can decide from there how to proceed. The summary: the versions of the antidote we are iterating through at the moment are not yet ready for human trial, but we have solved the toxicity problems and I believe we are close to a version that will either function wholly or not at all, thus reducing the risk of our first human subject sustaining damage or resulting in a burden of future care. The level of my confidence in that statement vacillates from day to day, of course.
